wydrukuj poleć znajomym zamów materiały
Od ilu lat pracuje Pani/Pan na różnych stanowiskach menedżerskich:

powyżej 20 lat
powyżej 15 lat
powyżej 10 lat
powyżej 5 lat
poniżej 5 lat
jeszcze nie byłam/-em menedżerem
nie chcę być menedżerem


Subskrypcja najnowszych ofert pracy





Nasi partnerzy:

rp.pl
gazeta.pl
onet.pl
interia.pl
wp.pl

CaridianBCT Releases Red Blood Cell Exchange Protocol in Canada 2010.05.20

LAKEWOOD, Colorado, USA - May 18, 2010 - CaridianBCT, a leading global provider of technology, products and services in the blood banking, transfusion medicine and cell therapy industries, today announced the protocol to perform Red Blood Cell Exchange (RBCX) on the Spectra Optia Apheresis System is now available for use in Canada.

Spectra Optia® Apheresis System
Photo: CaridianBCT
 
LAKEWOOD, Colorado, USA - May 18, 2010


CaridianBCT, a leading global provider of technology, products and services in the blood banking, transfusion medicine and cell therapy industries, today announced the protocol to perform Red Blood Cell Exchange (RBCX) on the Spectra Optia® Apheresis System is now available for use in Canada.

Red Blood Cell Exchange procedures are prescribed to treat various hematologic, metabolic and infectious diseases, primarily those diseases in which defective or damaged red blood cells play a major role in the pathology.

 
  Spectra Optia® Apheresis Product
Photo: CaridianBCT
 
The RBCX protocol
supplements the Spectra Optia system's Therapeutic Plasma Exchange (TPE) protocol-enabling health care professionals to select the most appropriate, individualized procedures to optimize patient care.

"Delivering additional protocols on the Spectra Optia system contributes to its enhanced versatility, performance and patient care for our customers," said Tom Jordan, senior vice president of Therapeutic Apheresis and Cell Therapy Systems at CaridianBCT.
"We are excited to launch the RBCX protocol in Canada, and are currently under FDA review for 510(k) clearance to release in the United States."

The RBCX protocol release in Canada follows the November 2009 launch in Europe, the Middle East and Africa (EMEA), Australia and areas of Asia.
Included in the family of protocols now available for the Spectra Optia system are the TPE protocol, available to EMEA, Australia, the United States and Canada and the Mononuclear Cell (MNC) protocol, launched in EMEA and Australia in October 2008.


About Spectra Optia Apheresis System


Based on COBE® Spectra system technology, the Spectra Optia system is a transportable therapeutic apheresis system that uses centrifugation for blood separation and a unique optical detection technology for interface management (Automated Interface Management system).

Spectra Optia® Apheresis Product
Photo: CaridianBCT
 
The Spectra Optia system
, tubing sets, and software have received a CE Mark and 510K clearance for the TPE protocol, and a CE Mark for the MNC and RBCX protocols.


About CaridianBCT


CaridianBCT is the leading global provider of innovative technologies and services specializing in automated blood collections, therapeutic apheresis and cell therapy systems, whole blood processes and pathogen reduction technologies.

 
 
The company serves patients through its commitment to better blood and better lives by developing and commercializing products that serve global customers in the blood banking, therapeutic apheresis and transfusion medicine industries.

For more information, visit

http://www.caridianbct.com/  


Contact:

Tarra Ryerson, Manager of Global Corporate Communications

Mobile: +1 303.246.3868
press@caridianbct.com  


http://www.caridianbct.com/location/north-america/about-caridianbct/press-room/Pages/18MAY,2010-CaridianBCT-Releases-Red-Blood-Cell-Exchange-Protocol-in-Canada.aspx  



Spectra Optia® Apheresis System



The Spectra Optia Apheresis System, based on the COBE Spectra system, is the industry's next-generation therapeutic apheresis and cell therapy platform that allows operators to spend more time focusing on patient care.

The Spectra Optia system is:

• Streamlined to provide quality apheresis procedures

• Continuous flow centrifugation technology complete with an Automated Interface Management (AIM) system for patient safety, and procedural efficiency

• Intuitive and easy to use, simplifying operator training

• A single platform for customized procedures to satisfy unique customer and patient needs

Spectra Optia® Apheresis System
Photo: CaridianBCT
 

Deliver versatility and performance:

• Multiple protocols on a single platform

• Tubing sets designed for multiple procedure types, minimizing training and reducing inventory and storage

Simplify operations:

• Convenient data management – Easy data storage and retrieval, with the ability to print or export information to address documentation requirements, reduce manual data transcription and improve data traceability

• Improved system mobility – A compact and stable design, including a collapsible monitor and IV pole, allows operators to easily move and store the system

Spend more time with patients, less time with technology:

• Focus on patient comfort and safety – Optimized fluid balance, customized anticoagulant infusion management and low extracorporeal volume tubing set

• Automated Interface Management – Perform real-time interface monitoring, interpretation and adjustment for flexible procedural control

• Intuitive touch screen and Graphical User Interface display – Access procedure data quickly and easily with fewer manual calculations

• Efficient screen navigation – Retrieve data for the right information, at the right time, in the right place

Spectra Optia® Apheresis System
Photo: CaridianBCT
 

The Spectra Optia Apheresis System is a transportable therapeutic apheresis system that uses continuous flow centrifugation and optical detection technology (Automated Interface Management or AIM system).

This advanced system offers operator choice and precision, and enables operators to perform a wide variety of procedures on one platform.

Spectra Optia® Apheresis System
Photo: CaridianBCT
 

Intuitive Graphical User Interface (GUI):

• Simplifies screen navigation by presenting important procedural information all at once, at the right time

• Provides simple data entry, enabling operator to enter data directly without manual calculations

Convenient data management:

• Easily store and retrieve data

• Quickly view information in the reports screen

• Print or export procedure data to a computer


Automated Interface Management (AIM):

• Performs real-time interface monitoring, interpretation and adjustment while retaining operator control capabilities

• Monitors the interface position and thickness of separated blood components

• Interprets interface information using unique optical detection software

• Adjusts the pumps and valves to manage the interface position and efficiently remove targeted components


Tubing set versatility

Ability to perform multiple procedures on one tubing set type that:

• Minimizes operator training, errors and handling

• Reduces inventory cost and storage space

• Offers low tubing set volume and low total blood volume (TBV) applications


http://www.caridianbct.com/location/north-america/products-and-services/Pages/spectra-optia-apheresis-system.aspx  



Apheresis Collections



At CaridianBCT, the art of blood collections begins by providing blood centers with the flexibility and advanced technology needed to safely collect more of the specific components patients require, thus ensuring our customers have the right product, at the right time and in the right place to positively impact patients' lives.

Apheresis Collections
Photo: CaridianBCT
 
Designed to optimize donations by collecting flexible combinations of blood components, the Trima Accel® Automated Blood Collection System simplifies the process of delivering the lifesaving gift of blood:

• Collect any blood component, in any combination

• Target specific blood types

• Respond quickly to fluctuations in demand

Superior patient care through advanced technology, operator choice and precision.
Photo: CaridianBCT
 

For an inclusive package, blood centers combine the Trima Accel system with one of CaridianBCT's powerful information systems to provide:

• Collection and procedural flexibility

• Capability to centrally manage and change priorities


http://www.caridianbct.com/location/north-america/our-markets/Pages/apheresis-collections.aspx  



Our Culture


CaridianBCT's strong culture is maintained through teamwork, collaboration and creative approaches to new ideas and problem-solving.
Employees are encouraged to practice innovative thinking, engage in lifelong learning and, above all, relentlessly pursue quality in all that we do.
This operational framework rewards results, relationships, cross-functionality and individual accountability.

CaridianBCT Values
Photo: CaridianBCT
 
As a company dedicated to the health and well-being of the global community, we support a vision, For Better Blood and Better Lives.
We carry out this vision with values that provide the structure for our business practices and day-to-day actions.

Recognizing our geographically and culturally diverse staff, CaridianBCT continuously seeks ways to help our people identify connections with colleagues and build relationships, creating bonds that empower us to influence others and get results both in and out of the office.

With a shared determination, collective wisdom and common goals, CaridianBCT has long attracted and retained the best and brightest employees.


http://www.caridianbct.com/location/north-america/contact-us/Pages/our-culture.aspx  



Tom Jordan
Senior Vice President and General Manager, Therapeutic Systems at CaridianBCT


Tom Jordan
Photo: CaridianBCT
 
As senior vice president and general manager, Tom Jordan has worldwide responsibility for the strategic direction and successful execution of the Therapeutic Apheresis and Cell Therapy Systems business area.
In this role, his responsibilities include planning, sales, marketing, business development, regulatory, medical liaison programs and multiple product development platforms for therapeutic apheresis, cell therapy and cell expansion technologies.
In addition, Jordan serves as a leader overseeing all operations in the Asia Pacific region.

Jordan has extensive experience in the health care industry, particularly in therapeutic application areas within medical devices, pharmaceutical, molecular diagnostics and international markets.

Prior to joining CaridianBCT, Jordan served as chief commercial operations officer at Clinical Micro Sensors Inc., a wholly owned subsidiary of Motorola.
He also has held leadership positions at Baxter International Inc. and Global Healthcare Exchange LLC.

Jordan received his bachelor's degree in business administration with a concentration in finance studies from the University of Iowa.
Jordan holds dual citizenship in Germany and the United States.


David Perez
President and Chief Executive Officer of CaridianBCT


David Perez
Photo: CaridianBCT
 
David Perez is president and chief executive officer of CaridianBCT, with more than two decades of leadership, management, commercial development, finance and operations experience in complex medical device and health care service businesses.
In this role, he guides the strategic direction, growth and execution of the global company and its mission to improve lives through innovation, quality and services delivered by the company's people, products and processes.

Currently, Perez is vice chair of the board of trustees for the National Blood Foundation (NBF), also serving on the NBF Council on Research and Development; a board member of the Foundation for America's Blood Centers®, and the Colorado BioScience Association; and on the board of directors at the Advanced Medical Technology Association (AdvaMed), as well as the chair of the Blood Products and Technology Sector for AdvaMed.

Prior to joining CaridianBCT in 1999, Perez held leadership positions at UroTherapies Inc., Haemonetics® Corp., Caremark LLC, Coram Healthcare Corp. and Kendall.

He earned his bachelor's degree in political science from Texas Tech University.

http://www.caridianbct.com/location/north-america/about-caridianbct/Pages/executive-leadership.aspx  



ASTROMAN magazine


wydrukuj ten artykuł
  strona: 1 z 1
polecamy artykuły
IBM and NVIDIA Collaborate to Expand Open Source Machine Learning Tools for Data Scientists
Blackbaud and Microsoft expand partnership with an integrated cloud initiative for nonprofits
Airbus and Atos awarded major cyber security contract to protect key the European Union institutions
Airbus Board of Directors Selects Guillaume Faury Future Chief Executive Officer
Hong Kong Small and Medium Enterprises Expand Global Footprint
Volvo FH milestone - millionth truck delivered at IAA in Hannover
Volvo Trucks presents future transport solution with autonomous electric vehicles
Prof. Andrzej K. Koźmiński: Trzy bariery dalszego rozwoju Polski
Volvo Trucks to introduce all-electric trucks in North America
Hong Kong: Smart Solutions for Fast-paced City
Ola Källenius to become Chairman of the Board of Management of Daimler AG in 2019
Lockheed Martin Selects Harris Corporation to Deliver F-35's Next Generation Computer Processor
Raytheon awarded production contract for Poland's Patriot
FTSE Russell promoted Poland from emerging market to developed market
Poland promoted to Developed Market status by FTSE Russell
strona główna  |  oferty pracy  |  executive search  |  ochrona prywatności  |  warunki używania  |  kontakt     RSS feed subskrypcja RSS
Copyright ASTROMAN © 1995-2018. Wszelkie prawa zastrzeżone.
Projekt i wykonanie: TAU CETI.